カテゴリ： GlobalData, アメリカ, 企業調査

Spark Therapeutics Inc (ONCE)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8296
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：105
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1. The company’s gene therapy vectors used in its programs are engineered using adeno-associated virus. Spark’s SPK-RPE65 is intentended to cure rare blinding conditions caused by mutations in the RPE65 gene. The company develops gene therapy products for the treatment of debilitating genetic diseases such as inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. It collaborates with pharma and biotech companies for its research and development activities. Spark is headquartered in Philadelphia, Pennsylvania, the US.

Spark Therapeutics Inc (ONCE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Spark Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Spark Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Spark Therapeutics Raises USD73 Million in Series B Financing 14
Spark Therapeutics Raises US$50 Million In Venture Financing 16
Partnerships 17
Spark Therapeutics Enters into partnership with University of Massachusetts Medical School 17
Licensing Agreements 18
Novartis Enters into Licensing and Supply Agreement with Spark Therapeutics 18
Spark Therapeutics Enters into Licensing Agreement with Genethon 19
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 20
Pfizer Amends Licensing Agreement with Spark Therapeutics 22
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 24
Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies 25
Spark Therapeutics Amends Licensing Agreement with University of Iowa Research Foundation 26
Spark Therapeutics Enters into Licensing Agreement with Children’s Hospital of Philadelphia 28
Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 29
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 30
Equity Offering 31
Spark Therapeutics Raises USD402.5 Million in Public Offering of Shares 31
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 33
Spark Therapeutics Raises USD181 Million in Public Offering of Shares 35
Spark Therapeutics Raises USD107 Million in Public Offering of Shares 37
Genable Tech to Raise USD15.7 Million in Financing 39
Spark Therapeutics Raises USD185 Million in IPO 40
Asset Transactions 42
JAZZ Pharma to Acquire Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 42
Acquisition 43
Spark Therapeutics Acquires Genable Technologies for USD15.3 Million 43
Spark Therapeutics Inc – Key Competitors 44
Spark Therapeutics Inc – Key Employees 45
Spark Therapeutics Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Strategy And Business Planning 47
Oct 11, 2018: Governor Wolf Announces Spark Therapeutics to Expand in West Philadelphia with New Facility, 500 New Jobs 47
Financial Announcements 48
Aug 07, 2018: Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress 48
May 08, 2018: Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress 51
Feb 20, 2018: Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress 53
Nov 07, 2017: Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress 55
Aug 02, 2017: Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress 57
May 09, 2017: Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress 60
Feb 22, 2017: Spark Therapeutics Reports 2016 Financial Results and Business Highlights 62
Corporate Communications 64
Jan 04, 2018: Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors 64
Sep 25, 2017: Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer 65
Product News 66
12/19/2017: FDA Approves Spark Therapeutics LUXTURNA (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy 66
11/02/2017: Spark Therapeutics to Participate in Multiple Upcoming Conferences 68
10/12/2017: FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease 69
07/10/2017: Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress 71
06/23/2017: Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress 73
04/06/2017: Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium 74
04/04/2017: Spark Therapeutics to Present Updated Hemophilia B Data at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium 75
03/26/2018: Boy with Inherited Blindness First to Receive FDA-Approved Gene Therapy at Bascom Palmer 76
03/21/2018: Childrens Hospital Los Angeles Treats First Patient on the West Coast Using Gene Therapy 77
03/20/2018: Mass. Eye and Ear performs first FDA-approved gene therapy procedure for inherited disease 78
03/05/2018: Horizon Blue Cross Blue Shield Provides Update on Voretigene neparvovec-rzyl (Luxturna) 79
01/03/2018: Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment 80
01/03/2018: Spark’s Gene Therapy Treatment for Blindness LUXTURNA to Cost $850,000 83
Product Approvals 85
Oct 19, 2017: Spark Therapeutics: Gene therapy continues to advance 85
Jul 31, 2017: Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA (voretigene neparvovec) 86
Jul 20, 2017: Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA (voretigene neparvovec) from FDA 88
Jul 17, 2017: Spark Therapeutics’ Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA 89
May 18, 2017: Spark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene Therapy Voretigene 91
Mar 01, 2017: Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency 92
Clinical Trials 93
Oct 08, 2018: Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate 93
Feb 23, 2018: Spark Therapeutics to Participate in Multiple Conferences in March 94
Nov 10, 2017: Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal Disease 95
Oct 12, 2017: Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy 97
Sep 06, 2017: Spark Therapeutics Announces Publication of Study Confirming Novel Tests Validity, Reliability and Ability to Detect Change in Functional Vision 99
Jul 13, 2017: Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec 101
Jan 09, 2017: Spark Therapeutics Announces U.S. Orphan Drug Designation Amendment and Study Updates for Lead Investigational Gene Therapy 103
Appendix 105
Methodology 105
About GlobalData 105
Contact Us 105
Disclaimer 105

List of Tables
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Spark Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Spark Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Spark Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Spark Therapeutics Raises USD73 Million in Series B Financing 14
Spark Therapeutics Raises US$50 Million In Venture Financing 16
Spark Therapeutics Enters into partnership with University of Massachusetts Medical School 17
Novartis Enters into Licensing and Supply Agreement with Spark Therapeutics 18
Spark Therapeutics Enters into Licensing Agreement with Genethon 19
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 20
Pfizer Amends Licensing Agreement with Spark Therapeutics 22
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 24
Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies 25
Spark Therapeutics Amends Licensing Agreement with University of Iowa Research Foundation 26
Spark Therapeutics Enters into Licensing Agreement with Children’s Hospital of Philadelphia 28
Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania 29
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 30
Spark Therapeutics Raises USD402.5 Million in Public Offering of Shares 31
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 33
Spark Therapeutics Raises USD181 Million in Public Offering of Shares 35
Spark Therapeutics Raises USD107 Million in Public Offering of Shares 37
Genable Tech to Raise USD15.7 Million in Financing 39
Spark Therapeutics Raises USD185 Million in IPO 40
JAZZ Pharma to Acquire Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 42
Spark Therapeutics Acquires Genable Technologies for USD15.3 Million 43
Spark Therapeutics Inc, Key Competitors 44
Spark Therapeutics Inc, Key Employees 45
Spark Therapeutics Inc, Subsidiaries 46

List of Figures
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Spark Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Spark Therapeutics Inc (ONCE)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Concho Resources Inc.：企業の戦略・SWOT・財務分析
    Concho Resources Inc. - Strategy, SWOT and Corporate Finance Report Summary Concho Resources Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Magma Fincorp Limited：企業のM&A・事業提携・投資動向
    Magma Fincorp Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Magma Fincorp Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Parker Hannifin Corp (PH)：企業の財務・戦略的SWOT分析
    Parker Hannifin Corp (PH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Air Transport Services Group, Inc.：企業の戦略・SWOT・財務情報
    Air Transport Services Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Air Transport Services Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Liechtensteinische Landesbank AG：企業の戦略・SWOT・財務情報
    Liechtensteinische Landesbank AG - Strategy, SWOT and Corporate Finance Report Summary Liechtensteinische Landesbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • UCB Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary UCB Inc (UCB), a subsidiary of UCB SA, is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, meta …
  • Daicel Corp (4202)：企業の財務・戦略的SWOT分析
    Daicel Corp (4202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Exillon Energy Plc (EXI)：石油・ガス：M&Aディール及び事業提携情報
    Summary Exillon Energy Plc (Exillon) is an oil exploration and production company. The company explores, produces and develops crude oil. Its services include drilling, exploration, appraisal, development, operations, management, and production services. Exillon’s operating assets are located in two …
  • Arden Partners Plc (ARDN)：企業の財務・戦略的SWOT分析
    Summary Arden Partners Plc (Arden) is a multi-service stockbroker that provides a range of financial services to corporate and institutional clients. The company offers research, distribution, execution and corporate finance services. Arden distribution services include providing unique trading thou …
  • Duke Energy Ohio Inc：企業の戦略的SWOT分析
    Duke Energy Ohio Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • China National Petroleum Corporation-石油・ガス分野：企業M&A・提携分析
    Summary China National Petroleum Corporation (CNPC) is an integrated oil and gas company that produces and supplies oil and gas and petrochemical products. The company explores, develops and produces hydrocarbons in onshore and offshore areas of China, Canada, Africa, Central Asia and Russia, Latin …
  • MDU Resources Group, Inc.：企業の戦略・SWOT・財務情報
    MDU Resources Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary MDU Resources Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • The Procter & Gamble Co：企業のM&A・事業提携・投資動向
    The Procter & Gamble Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Procter & Gamble Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Anagin Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Anagin Inc (Anagin) formerly Anagin LLC, is a biotechnology company which develops novel targeted therapies for the treatment of neuropsychiatric diseases. The company is focused on the development of first-in-class small molecule modulators of neurotransmitter signaling complexes that reduc …
  • Yissum Research Development Company of the Hebrew University of Jerusalem Ltd-医療機器分野：企業M&A・提携分析
    Summary Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (YRDC) is a technology transfer company that offers marketing the inventions and know-how generated by the University's researchers and students. The company’s products include exelon, doxil, cherry tomatoes and lo …
  • Showa Aircraft Industry Co., Ltd.：企業の戦略・SWOT・財務分析
    Showa Aircraft Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Showa Aircraft Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Advanced Accelerator Applications SA：医療機器：M&Aディール及び事業提携情報
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • Pembina Pipeline Corp (PPL)：企業の財務・戦略的SWOT分析
    Pembina Pipeline Corp (PPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Hewlett Packard Enterprise Company：企業の戦略・SWOT・財務分析
    Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report Summary Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • EnviroMission Limited：企業の戦略的SWOT分析
    EnviroMission Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆